Seek Labs Announces Partnership with Cerbrec to Accelerate Diagnostic and Therapeutic Innovation with Graphbook Software
November 14, 2024
Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and rapid response therapeutic technologies, is pleased to announce a new partnership with Cerbrec, a cutting-edge data solutions provider. Seek Labs will integrate Cerbrec’s flagship Graphbook software into company operations, which will enhance company-wide research and development efforts to accelerate our mission to make a transformative impact on global health.
The addition of Graphbook software will help the Seek Labs team efficiently organize, interpret, and leverage complex data sets by streamlining data processes. This strategic partnership is a significant milestone in Seek Labs’ commitment to advancing accessible healthcare solutions through diagnostic and therapeutic technologies. The Seek Labs team plans to immediately implement Graphbook’s features into the research and development of our programmable rapid response therapeutic platform.
“We are excited to unlock new efficiencies and insights through our exciting partnership with Cerbrec,” said Jared Bauer, CEO of Seek Labs. “Graphbook will empower us to address critical healthcare needs through innovative technologies and products faster and with greater precision.”
This collaboration represents a leap forward in Seek Labs’ research and development with enhanced data-driven decision-making. As Seek Labs integrates Graphbook into its workflow, we can further our mission to make high-impact healthcare solutions more accessible to patients globally.
“We’re thrilled to bring Cerbrec’s AI-driven data solutions platform to accelerate Seek Labs’ transformative research and development,” said Garrett Wang, CEO of Cerbrec. “Our strength in high-performance computing addresses challenges in large-scale data processing and data integration. We’re proud to support Seek Labs’ pioneering work in diagnostic and therapeutic innovations.”
About Seek Labs
Seek Labs is developing new solutions in point-of-care molecular diagnostics and programmable target ablation technologies that have the potential to revolutionize the detection and treatment of diseases. Seek Labs innovated the SeekIt™ platform, the world’s first standalone molecular diagnostic testing platform that integrates the essential components of molecular diagnostics, unlocking a new generation of testing that empowers patients with accurate and rapid information about their health–wherever they are. Seek Labs is also developing a programmable rapid response therapeutic platform for target ablation that leverages CRISPR technology. The platform seeks and destroys infectious pathogens and disease-driving sequences, which enables rapid design, development, and deployment of programmable therapeutic products.
Seek Labs is headquartered in Salt Lake City, Utah. Seek Labs is a proud member of the BioHive, a collective representing the life science and healthcare innovation ecosystem in Utah. BioHive is dedicated to all the ways our work can positively impact the lives of our community, our teams, and patients.
Recent News
- Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
- Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development
- NUSANO STABLE ISOTOPE PROGRAM ENRICHES GADOLINIUM-160 TO 99.2% PURITY
- CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
- Seek Labs Unveils BioSeeker™
- Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
